vs
Axe Compute Inc.（AGPU）与Bone Biologics Corp（BBLG）财务数据对比。点击上方公司名可切换其他公司
Axe Compute Inc.的季度营收约是Bone Biologics Corp的34.0倍（$8.7K vs $255）。Bone Biologics Corp净利率更高（-339596.1% vs -1740028.0%，领先1400431.9%）。Axe Compute Inc.同比增速更快（-1.3% vs -54.1%）
Bone Biologics Corp是一家临床阶段生物技术企业，专注研发用于脊柱融合等骨科手术的骨再生修复生物制剂，主要面向美国医疗市场，核心业务覆盖骨科护理及再生医学领域。
AGPU vs BBLG — 直观对比
营收规模更大
AGPU
是对方的34.0倍
$255
营收增速更快
AGPU
高出52.8%
-54.1%
净利率更高
BBLG
高出1400431.9%
-1740028.0%
损益表 — Q4 2025 vs Q1 2024
| 指标 | | |
|---|---|---|
| 营收 | $8.7K | $255 |
| 净利润 | $-150.9M | $-866.0K |
| 毛利率 | — | — |
| 营业利润率 | -1990880.1% | -354327.8% |
| 净利率 | -1740028.0% | -339596.1% |
| 营收同比 | -1.3% | -54.1% |
| 净利润同比 | -6856.6% | 76.7% |
| 每股收益（稀释后） | — | $-1.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGPUBBLG
| Q4 25 | $8.7K | — | ||
| Q3 25 | $3.6K | — | ||
| Q2 25 | $2.7K | — | ||
| Q1 25 | $110.3K | — | ||
| Q4 24 | $8.8K | — | ||
| Q3 24 | $3.9K | — | ||
| Q2 24 | $67.3K | — | ||
| Q1 24 | $4.9K | $255 |
净利润AGPUBBLG
| Q4 25 | $-150.9M | — | ||
| Q3 25 | $-77.7M | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-2.4M | — | ||
| Q4 24 | $-2.2M | — | ||
| Q3 24 | $-3.1M | — | ||
| Q2 24 | $-3.2M | — | ||
| Q1 24 | $-4.2M | $-866.0K |
毛利率AGPUBBLG
| Q4 25 | — | — | ||
| Q3 25 | -131.0% | — | ||
| Q2 25 | -579.4% | — | ||
| Q1 25 | 59.1% | — | ||
| Q4 24 | -250.5% | — | ||
| Q3 24 | -186.1% | — | ||
| Q2 24 | 79.4% | — | ||
| Q1 24 | -361.8% | — |
营业利润率AGPUBBLG
| Q4 25 | -1990880.1% | — | ||
| Q3 25 | -90654.1% | — | ||
| Q2 25 | -99174.8% | — | ||
| Q1 25 | -2073.3% | — | ||
| Q4 24 | -23848.9% | — | ||
| Q3 24 | -55296.7% | — | ||
| Q2 24 | -3664.6% | — | ||
| Q1 24 | -73734.7% | -354327.8% |
净利率AGPUBBLG
| Q4 25 | -1740028.0% | — | ||
| Q3 25 | -2146264.3% | — | ||
| Q2 25 | -77198.4% | — | ||
| Q1 25 | -2214.6% | — | ||
| Q4 24 | -24676.9% | — | ||
| Q3 24 | -79208.9% | — | ||
| Q2 24 | -4730.1% | — | ||
| Q1 24 | -86843.2% | -339596.1% |
每股收益（稀释后）AGPUBBLG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-1.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.8M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $47.7M | $3.7M |
| 总资产 | $52.9M | $3.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AGPUBBLG
| Q4 25 | $10.8M | — | ||
| Q3 25 | $181.7K | — | ||
| Q2 25 | $506.1K | — | ||
| Q1 25 | $3.1M | — | ||
| Q4 24 | $611.8K | — | ||
| Q3 24 | $3.1M | — | ||
| Q2 24 | $5.3M | — | ||
| Q1 24 | $5.2M | — |
股东权益AGPUBBLG
| Q4 25 | $47.7M | — | ||
| Q3 25 | $-77.4M | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-145.8K | — | ||
| Q4 24 | $-202.6K | — | ||
| Q3 24 | $2.0M | — | ||
| Q2 24 | $4.1M | — | ||
| Q1 24 | $4.1M | $3.7M |
总资产AGPUBBLG
| Q4 25 | $52.9M | — | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $3.4M | — | ||
| Q1 25 | $5.9M | — | ||
| Q4 24 | $5.0M | — | ||
| Q3 24 | $7.5M | — | ||
| Q2 24 | $10.6M | — | ||
| Q1 24 | $10.6M | $3.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.9M | $-1.3M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AGPUBBLG
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $-1.7M | — | ||
| Q2 25 | $-3.3M | — | ||
| Q1 25 | $-985.8K | — | ||
| Q4 24 | $-2.1M | — | ||
| Q3 24 | $-2.5M | — | ||
| Q2 24 | $-3.2M | — | ||
| Q1 24 | $-3.4M | $-1.3M |
自由现金流AGPUBBLG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-2.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-3.4M | — |
自由现金流率AGPUBBLG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -23429.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -70379.8% | — |
资本支出强度AGPUBBLG
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 73.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 62.4% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
